Search

Paul J Jarosz

from Mountain View, CA
Age ~71
Get Report
Also known as:
Paul Dr Jarosz, Paul A Jarosz, Paul Jorosz, Paul Z
Related to:
Lupe S Gonzales, 61David Gonzales, 66Donald Mendez, 52Cecylia GonzalezScott A Mendez, 42Enrique Gonzalez, 35
Connected to:
Cody M Jarosz, 32Dorothy A Jarosz, 72Francesca D Jarosz, 39Jesse L Jarosz, 46Kathryn H Jarosz, 68Leszek P Jarosz, 57Tomasz P Jaroszek, 42Byron J Jarquin, 61Darren R Jarquin, 41Jackie Jarquin, 52

Paul Jarosz Phones & Addresses

  • Mountain View, CA
  • 10917 Legacy Ridge Ct, Westminster, CO 80031 (303) 410-1238 (303) 410-1239 (303) 439-9223
  • 9100 Vance St, Broomfield, CO 80021
  • Thornton, CO
  • Steamboat Springs, CO
  • Denver, CO
  • Los Altos, CA
  • Lincoln, NE

Professional Records

License Records

Paul Joseph Jarosz Rp

License #:
8687 - Expired
Category:
Pharmacy
Issued Date:
Jun 24, 1976
Effective Date:
Dec 24, 2015
Expiration Date:
Jan 1, 2016
Type:
Pharmacist

Resumes

Resumes

Paul Jarosz Photo 1

Sole Proprietor

View page
Location:
10917 Legacy Ridge Way, Westminster, CO 80031
Industry:
Biotechnology
Work:
Geneva Pharmaceuticals 1996 - 1999
Senior Vice President, Development
Novartis 1996 - 1999
Senior Vice President, Development, Geneva Pharmaceuticals
Jarosz Consulting 1996 - 1999
Sole Proprietor
Syntex Research 1991 - 1996
Director, Formulation Development
Syntex Management Systems, Inc. 1991 - 1996
Director, Formulation Development
Education:
University of Iowa 1977 - 1981
Doctorates, Doctor of Philosophy, Pharmacy University of Nebraska Medical Center 1971 - 1976
Bachelors, Bachelor of Science, Pharmacy
Skills:
Pharmaceutical Industry
Biotechnology
Drug Delivery
Technology Transfer
Formulation
Drug Development
Gmp
Pharmaceutics
Validation
Fda
Drug Discovery
Generic Programming
Regulatory Affairs
R&D
Life Sciences
Process Optimization
Oncology
U.s. Food and Drug Administration
Product Development
Biopharmaceuticals
Sop
V&V
Clinical Development
Commercialization
21 Cfr Part 11
Cmc
Regulatory Submissions
Chemistry
Lifesciences
Hplc
Analytical Chemistry
Glp
Chromatography
Research and Development
Formulation Development
Cgmp
Pharmaceutical Development
Process Validation
Paul Jarosz Photo 2

Paul Jarosz

View page
Paul Jarosz Photo 3

Paul Jarosz

View page
Paul Jarosz Photo 4

Paul Jarosz

View page
Location:
United States

Business Records

Name / Title
Company / Classification
Phones & Addresses
Paul Jarosz
Chief Operating Officer
Gonex Inc
Commercial Physical Research
7034 Indian Peaks Trl, Boulder, CO 80301
(303) 581-0343

Publications

Us Patents

Method For Inactivating Gonadotrophs

View page
US Patent:
6924268, Aug 2, 2005
Filed:
Jan 21, 2002
Appl. No.:
10/054552
Inventors:
Torrance M. Nett - Ft. Collins CO, US
Leonard Michael Glode - Golden CO, US
Maciej Wieczorek - Superior CO, US
Paul J. Jarosz - Westminster CO, US
Assignee:
Colorado State University Research Foundation - Fort Collins CO
International Classification:
A61K038/00
US Classification:
514 12, 514 14, 530313, 530328, 530402
Abstract:
Certain toxic compounds (T) such as, for example, compounds based upon diphtheria toxin, ricin toxin, pseudomonas exotoxin, α-amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the gonadotrophs of the animal's anterior pituitary gland. Hence such compounds may be used to sterilize such animals and/or to treat certain sex hormone related diseases.

Method For Inactivating Gonadotrophs

View page
US Patent:
20050277582, Dec 15, 2005
Filed:
Jul 29, 2005
Appl. No.:
11/192754
Inventors:
Torrance Nett - Bellvue CO, US
Leonard Glode - Golden CO, US
Maciej Wieczorek - Superior CO, US
Paul Jarosz - Westminster CO, US
International Classification:
A61K038/24
US Classification:
514008000
Abstract:
Certain toxic compounds (T) such as, for example, compounds based upon diphtheria toxin, ricin toxin, pseudomonas exotoxin, .alpha.-amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the gonadotrophs of the animal's anterior pituitary gland. Hence such compounds may be used to sterilize such animals and/or to treat certain sex hormone related diseases.

Enoximone Formulations And Their Use In The Treatment Of Cardiac Hypertrophy And Heart Failure

View page
US Patent:
20060018970, Jan 26, 2006
Filed:
Dec 13, 2004
Appl. No.:
11/010830
Inventors:
Michael Bristow - Cherry Hills Village CO, US
Richard Gorczynski - Westminster CO, US
Norve Webb - Loveland OH, US
Jack Domet - Cincinnati OH, US
Dhiren Shah - Leawood KS, US
Paul Jarosz - Westminster CO, US
International Classification:
A61K 31/4166
A61K 9/14
US Classification:
424489000, 514389000
Abstract:
The present invention provides formulations of the drug enoximone that include 40% to 80% non-ionic surfactant. Also provided a methods of treating heart failure and cardiac hypetrophy with these formulations.

High Dose Formulations

View page
US Patent:
54550459, Oct 3, 1995
Filed:
May 13, 1993
Appl. No.:
8/061656
Inventors:
Glenn J. Samuels - Sunnyvale CA
Jung-Chung Lee - San Jose CA
Charles Lee - Union City CA
Stephen Berry - Saratoga CA
Paul J. Jarosz - Los Altos CA
Assignee:
Syntex (U.S.A.) Inc. - Palo Alto CA
International Classification:
A61K 948
US Classification:
424451
Abstract:
Mycophenolate mofetil and mycophenolic acid can be conveniently manufactured into high dose oral formulations by the hot melt filling of a supercooled mycophenolate mofetil or mycophenolic acid liquid into a pharmaceutical dosage form. High dose oral pharmaceutical formulations and manufacturing methods therefor are disclosed.

Hormone-Recombinant Toxin Compounds And Methods For Using Same

View page
US Patent:
63264676, Dec 4, 2001
Filed:
Apr 19, 2000
Appl. No.:
9/551933
Inventors:
Torrance M. Nett - Bellvue CO
Leonard Michael Glode - Golden CO
Maciej Wieczorek - Superior CO
Paul J. Jarosz - Westminster CO
Assignee:
Colorado State University Research Foundation - Fort Collins CO
International Classification:
A61K 3800
C07K 500
C07K 700
US Classification:
530328
Abstract:
Certain toxic compounds (T) such as, for example, compounds based upon diphtheria toxin, ricin toxin, pseudomonas exotoxin,. alpha. -amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the gonadotrophs of the animal's anterior pituitary gland. Hence such compounds may be used to sterilize such animals and/or to treat certain sex hormone related diseases.

High Dose Ranolazine Formulations

View page
US Patent:
54727073, Dec 5, 1995
Filed:
May 9, 1994
Appl. No.:
8/239621
Inventors:
Glenn J. Samuels - Sunnyvale CA
Jung-Chung Lee - San Jose CA
Charles Lee - Union City CA
Stephen Berry - Saratoga CA
Paul J. Jarosz - Los Altos CA
Assignee:
Syntex (U.S.A.) Inc. - Palo Alto CA
International Classification:
A61K 948
C07D26530
C07D29500
US Classification:
424451
Abstract:
Mycophenolate mofetil, mycophenolic acid, and ranolazine can be conveniently manufactured into high dose oral formulations by the hot melt filling of a supercooled mycophenolate mofetil, mycophenolic acid, or ranolazine liquid into a pharmaceutical dosage form. High dose oral pharmaceutical formulations and manufacturing methods therefor are disclosed.

High Dose Formulations Of Mycophenolate Mofetil And Mycophenolic Acid

View page
US Patent:
55543847, Sep 10, 1996
Filed:
Jun 2, 1995
Appl. No.:
8/459227
Inventors:
Glenn J. Samuels - Sunnyvale CA
Jung-Chung Lee - San Jose CA
Charles Lee - Union City CA
Stephen Berry - Saratoga CA
Paul J. Jarosz - Los Altos CA
Assignee:
Syntex (U.S.A.) Inc. - Palo Alto CA
International Classification:
A61K 948
US Classification:
424451
Abstract:
Mycophenolate mofetil and mycophenolic acid can be conveniently manufactured into high dose oral formulations by the hot melt filling of a supercooled mycophenolate mofetil or mycophenolic acid liquid into a pharmaceutical dosage form. High dose oral pharmaceutical formulations and manufacturing methods therefor are disclosed.
Control profile
Paul J Jarosz from Mountain View, CA, age ~71 Get Report